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Abstract
The pattern of cerebral dopamine (DA) abnormalities in Huntington disease (HD) is complex, as reflected by the variable
clinical benefit of both DA antagonists and agonists in treating HD symptoms. In addition, little is known about serotonin
metabolism despite the early occurrence of anxiety and depression in HD. Post-mortem enzymatic changes are likely to
interfere with the in vivo profile of biogenic amines. Hence, in order to reliably characterize the regional and chronological
profile of brain neurotransmitters in a HD mouse model, we used a microwave fixation system that preserves in vivo
concentrations of dopaminergic and serotoninergic amines. DA was decreased in the striatum of R6/2 mice at 8 and 12
weeks of age while DA metabolites, 3-methoxytyramine and homovanillic acid, were already significantly reduced in 4-
week-old motorically asymptomatic R6/2 mice. In the striatum, hippocampus and frontal cortex of 4, 8 and 12-week-old R6/
2 mice, serotonin and its metabolite 5-hydroxyindoleacetic acid were significantly decreased in association with a decreased
turnover of serotonin. In addition, automated high-resolution behavioural analyses displayed stress-like behaviours such as
jumping and grooming and altered spatial learning in R6/2 mice at age 4 and 6 weeks respectively. Therefore, we describe
the earliest alterations of DA and serotonin metabolism in a HD murine model. Our findings likely underpin the
neuropsychological symptoms at time of disease onset in HD.
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Introduction
Huntington disease (HD) is an autosomal dominant neurode-
generative disease with complete penetrance. HD is caused by a
CAG repeat expansion in the HTT gene that encodes huntingtin
[1,2]. Individuals who are at risk can have access to predictive
genetic testing in order to determine whether they have inherited
the expanded CAG trinucleotide repeat. HD is characterised by
progressive motor dysfunction, cognitive decline, and psychiatric
disturbance with an age of onset usually between 30 and 50 years
old. The concept of ‘‘phenoconversion’’ or ‘‘motor onset’’ does not
account for the many individuals who show cognitive or
behavioural disturbances several years before the onset of motor
symptoms. In particular, anxiety, depression and irritability are
prominent symptoms in presymptomatic HD carriers but are too
infrequently recognized and therefore undertreated [3,4].
Dopamine (DA) alterations have been reported in murine
models of HD [5] and post-mortem tissues from HD patients [6] and
may account for both motor and non-motor manifestations of the
disease. In particular, DA receptors, i.e. D1 and D2 receptors, and
DA uptake sites are reduced in symptomatic HD patients [7,8] but
also in presymptomatic HD carriers [9] suggesting an early
dysfunctional DA signalling in HD. Transcriptional deregulation
plays an important role in the pathophysiology of HD and the
expression of DA receptors is decreased in HD [10]. However,
both DA antagonists [11] and agonists [12] have shown some
clinical benefit in treating HD symptoms. Schizophrenia-like
symptoms can be seen in the early stages of HD and may reflect a
hyperdopaminergic state. Similarly, DA depleting treatments such
as tetrabenazine, an inhibitor of the vesicular monoamine
transporter VMAT-2, improves abnormal movements, i.e. chorea.
Although it is possible that some of these apparent contradictory
results reflect the dynamic changes that occur in the DA system
during the progression of HD, technical bias inherent to the
methods of tissue collection may also be at fault. In addition,
serotonin (5-HT) metabolism has been little characterized in HD
[13,14]. In particular, post-mortem enzymatic changes are likely to
interfere with the in vivo profile of biogenic amines [15]. In an
attempt to circumvent this limitation, and in order to better
address the kinetics of DA and serotonin metabolites in R6/2 mice
at different stages of the disease, we used a microwave fixation
system that instantaneously inactivates brain enzymes while
preserving the structure of the brain for regional dissection.
Materials and Methods
Mice
All animals were handled in strict accordance with good animal
practice as defined by the Texas animal welfare bodies, and all
animal work was approved by the institutional animal care and use
committee at the Baylor Research Institute, Dallas, TX
(#007_001). Four, 8 and 12-week-old transgenic R6/2 mice and
wild-type littermates obtained from Jackson Laboratory (Bar
Harbor, ME, USA) were maintained on a 12 h lights on 12 h
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4–5 per cage in an enriched environment. They were given ad
libitum access to food and water. At two weeks of age tail snips were
obtained and sent to Laragen Inc. (Los Angeles, CA), for
genotyping and sequencing of CAG repeats. The number of
CAG repeats from our R6/2 mouse colony ranged from 106 to
126. Mice were also genotyped for the Pde6d gene (Laragen Inc,
LA, CA, USA) since Pde6d mut/mut is present in about 30% of
R6/2 mice bred in a manner where C57BL6CBA is crossed to
C57BL6 CBA F1 hybrids. We excluded from the analyses mice
that were homozygous for the Pde6d mutation since these mice
develop blindness overtime [16], representing a confounding
factor in neurobehavioural analyses, and in particular for spatial
learning tasks.
Collection of brain samples after microwave fixation
Mice were killed by focused microwave irradiation using a
10 kW Muromachi Microwave Applicator, Model TMW-4012C
(Stoelting Co., Wood Dale, IL, USA), as detailed [17]. The system
has a specially designed applicator unit that radiates a large
amount of microwave energy in a short period of time on a rat or
mouse, restrained in the applicator. In addition, the use of a water
jacket surrounding the animal holder allows a homogenous
repartition of the irradiation on the whole brain surface. Water
becomes hot after irradiation and therefore was replaced with new
water every time a new mouse was placed. Exposure time, power
and position of the holder in the applicator unit were adjusted
incrementally to the right settings for each weight/age group using
the Muromachi machine. Since exposure time to the focused
microwaves was less than 1 second for each animal, there was no
concern about animal welfare. Regional dissection was performed
on ice in order to isolate striatum, hippocampus and frontal cortex.
Following dissection, samples were immediately placed on dry ice
and then kept frozen at 280uC until tissue assay.
Measurement of dopaminergic and serotoninergic
amines by HPLC
Tissues were thawed and deproteinized with a volume of
perchloric acid (0.4 M) containing DETAPAC (1 mg/ml) and
DTE (0.1 mg/ml) such that the dilution factor was 10. After
centrifugation, a 5 mL of clear perchloric acid extract was injected
directly into the amine HPLC system. DA, 5-HT and their
metabolites – 3,4-dihydroxyphenylacetic acid (DOPAC), 3-ortho-
methyldopa (3-OMD), 3-methoxytyramine (3-MT), homovanillic
acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) – were
separated on an HPLC column (C18 25063 mm, 5 m, Phenom-
enex, CA); at a flow rate of 0.5 ml/min with a mobile phase
consisting of potassium phosphate (0.05 mM), octylsulfate (1 mM)
and 14% methanol, adjusted to pH 2.65. Detection was
performed using a coulometric electrochemical cell (model
5014B, ESA Inc, Chelmsford, MA) set to a potential of
+400 mV. Data were acquired and processed using Coularray
for Windows software (ESA Inc, Chelmsford, MA).
Behavioural studies
Home cage. Four digital video cameras were mounted
perpendicular to the cages. Video data were analyzed by
HomeCageScan software (Clever Systems, Reston, VA, USA).
During recording, mice were housed in polycarbonate cages (Lab
Product, Seaford, DE, USA) to improve the video tracking of the
mice, with minimal bedding (80 ml) to minimize mounding, which
can obscure the mouse. Each mouse was recorded individually for
24 h, with 12 h daylight and 12 h dim red light, and then returned
to its cage with its littermates. A set of videos were hand scored and
compared with HomeCageScan scoring in order to ensure that
data encryption was accurate. Among the panel of behaviours that
can be analyzed using the HomeCageScan technology [18],
hanging, jumping and grooming were selected in view of their
relevance to the biochemical profiles that were obtained after
microwave fixation. Hanging behaviors were detected when the
animal was suspended from the cage top. Grooming was recorded
if the animal’s body deformed over a defined criteria and over a
certain minimum time period, while the animal was situated in the
same place. It also required that the animal be in a set of possible
postures; likewise, the deformation criteria defined possible shape
change patterns over time. Jumping was defined as any movement
from a lower position to a higher position and quickly back down
to the lower position. It typically required quick elevation of the
lower end of the animal above the bedding floor and return back
to the bedding floor. Data were expressed as percent of time. We
recorded R6/2 and WT mice at 4, 8 and 12 weeks of age.
Barnes maze. We used a circular platform (91 cm of
diameter) with 20 equally spaced holes (5 cm diameter) along
the perimeter and elevated 90 cm above the floor (Stoelting,
Wood Dale, IL). Video tracking was performed using TopScan
software (Clever Syst, Reston, VA). For stimulus/reinforcement,
we used a combination of bright light and 4 equidistant fans
blowing air on the table. Visual cues consisted of figures with
various shapes and colours. The maze was cleaned out between
each mouse using a solution with 1% Incidin solution to avoid
olfactory cues. The protocol was adapted from Nature protocols.
Briefly, after an adaptation period to the tunnel on day 1, the mice
received 2 trials per day with an inter-trial interval of 30 minutes
during 4 consecutive days. The probe trials were conducted on day
5 and day 12 in order to test short- and long-term retention.
Number of pokes (errors) in each hole and latency to reach the
virtual target hole were measured on day 1, 2, 3 and 4. Number of
pokes in the target hole (targets) and latency to reach the virtual
target hole were measured on day 5 and 12 in order to assess both
short- and mid-term retention memory.
Statistics
For comparison of means and correlations, parametric (AN-
OVA and Pearson) or non-parametric tests (Spearman) were used
as appropriate.
Results
Altered DA and serotonin metabolism in R6/2 mice
After verifying that there were no differences between male and
female mice for each genotype sacrificed by focused microwave
irradiation (data not shown), the values obtained for each
metabolite were pooled for both sexes. We found a significant
decrease of DA in the striatum of R6/2 mice at 8 and 12 weeks of
age, as well as in the hippocampus and frontal cortex of 12-week-
old R6/2 mice compared to WT littermates (Table 1). DA
metabolites, DOPAC, 3-MT and HVA, were significantly
decreased at age 8 and 12 weeks in the striatum, hippocampus
and/or frontal cortex of R6/2 mice (Table 1). A significant
decrease of striatal DOPAC, 3-MT and HVA was also observed in
4-week-old R6/2 mice (Table 1). In addition, we found
significantly reduced 3-MT/DA ratio in the striatum and HVA/
DA ratio in the striatum and frontal cortex of R6/2 mice at 4, 8
and 12 weeks of age (Table 1). No overt difference was detected for
3-OMD between R6/2 and WT mice (Table 1).
Furthermore, in all 3 regions analyzed – striatum, hippocampus
and frontal cortex – we found significantly decreased 5-HT and 5-
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littermates (Table 2). The ratio of 5-HIAA to 5-HT was also quite
significantly decreased in the striatum, hippocampus and frontal
cortex of 4, 8 and 12-week-old R6/2 mice (Table 2) suggesting
reduced serotonin turnover in HD mice [19]. We did not find any
correlation between the number of CAG repeats and serotonin-
ergic or dopaminergic amines.
Of note, compared to mice that were sacrificed using CO2
asphyxiation, mice that were sacrificed by focused microwave
irradiation displayed significantly lower striatal levels of dopami-
nergic metabolites, and especially a 4-fold difference in DOPAC
and a 15-fold difference in 3-MT, but a 2-fold increase in 5-HT in
the striatum (data not shown).
Increased stress-like behaviours and altered spatial
learning in R6/2 mice
Home Cage. We did not find any difference between males
and females for the different phenotypes of interest (Figure 1).
However, the parameters were analyzed separately for male and
female since body weight can be a confounding factor for motor
functions in mice. We found a significant decrease of total time
spent hanging in 8 and 12-week-old R6/2 males and females
compared to WT (Figure 1A). These decrements were similar in
both light and dark phases (data not shown). However, we did not
observe any abnormality in hanging (Figure 1A), or other
locomotor phenotype, in HD mice at 4 weeks of age indicating
that the mice were motorically asymptomatic at this age.
Importantly, repetitive behaviours recognized as stress-like
behaviours [20,21] were already present at 4 weeks of age with
significantly increased grooming behaviours in R6/2 males
(Figure 1B) and jumps in both R6/2 males and females
(Figure 1C). At age 8 and 12 weeks, grooming and jumping
behaviours remained significantly increased in R6/2 males and
females (Figures 1B and 1C).
Barnes maze. The Barnes maze test was performed at 6
weeks of age, i.e. at a presymptomatic age for motor phenotype in
R6/2 mice. After verifying that there were no differences between
male and female mice for each genotype (data not shown), the
values obtained for each parameter of the Barnes maze test were
pooled for both sexes. We found significantly increased latency to
reach the target hole at day 1 in R6/2 mice compared to WT
littermates (t=81675 sec vs 28620 sec, p=0.013) as well as day
2( t=5 2 639 sec vs 23614 sec, p=0.010), day 3 (t=44634 sec vs
20613, p=0.017) and day 4 (t=32620 sec vs 18610 sec,
p=0.019). R6/2 mice also made significantly more errors at day
1( n = 1 0 67v s5 64, p=0.046) and day 3 (n=964v s6 63,
Table 1. Profile of dopamine metabolites in brain of WT and R6/2 mice at 4, 8 and 12 weeks of age.
GENOTYPE AGE REGION N 3-OMD DA DOPAC 3-MT HVA 3MT/DA HVA/DA
(weeks) (nmol/g) (nmol/g) (nmol/g) (nmol/g) (nmol/g)
R6/2 4 Striatum 17 0.32960.058 38.163.8 1.9760.30 0.20860.043 3.7860.57 0.005460.0009 0.10060.013
WT 18 0.32460.048 40.065.8 2.4960.47 0.26760.053 4.7261.01 0.006360.0014 0.11960.015
p value NS NS 0.002 0.003 0.005 0.021 ,0.001
R6/2 4 Hippocampus 17 0.32460.067 0.72860.199 0.05060.042 0.01560.019 0.22460.044 0.018360.0246 0.34660.098
WT 18 0.32660.051 0.77760.226 0.05760.039 0.01560.016 0.27060.066 0.016860.0202 0.35560.067
p value NS NS NS NS 0.035 NS NS
R6/2 4 Frontal Cortex 16 0.32160.073 4.6761.43 0.44960.151 0.03460.035 1.08860.320 0.006360.0062 0.25160.062
WT 17 0.31060.064 4.4762.47 0.48660.213 0.02560.022 1.15760.361 0.006760.0079 0.32260.122
p value NS NS NS NS NS NS 0.043
R6/2 8 Striatum 15 0.33060.060 39.367.0 1.6560.25 0.21060.050 2.6060.48 0.005560.011 0.06660.009
WT 15 0.31060.050 59.6611.2 3.1560.65 0.45060.090 5.8861.21 0.007860.0016 0.10060.017
p value NS ,0.001 ,0.001 ,0.001 ,0.001 ,0.001 ,0.001
R6/2 8 Hippocampus 15 0.32860.058 0.93060.310 0.20960.161 0.03360.009 0.23360.125 0.040760.0198 0.29860.273
WT 15 0.31560.048 1.04060.260 0.21760.163 0.05260.020 0.39760.142 0.053360.0256 0.39260.130
p value NS NS NS 0.004 0.002 NS NS
R6/2 8 Frontal Cortex 15 0.31260.065 5.5662.76 0.56460.213 0.05260.014 0.79860.220 0.012560.0093 0.17060.072
WT 14 0.30460.036 7.1762.65 0.80860.263 0.08560.031 1.63460.468 0.014760.0127 0.26060.120
p value NS NS 0.011 0.002 ,0.001 NS 0.02
R6/2 12 Striatum 18 0.27560.072 25.965.2 0.7660.29 0.15660.036 1.7760.42 0.006160.0013 0.06860.008
WT 15 0.23060.030 55.0611.1 2.3960.97 0.39060.080 4.9561.06 0.007260.0010 0.09160.017
p value 0.025 ,0.001 ,0.001 ,0.001 ,0.001 0.007 ,0.001
R6/2 12 Hippocampus 18 0.23760.051 0.71060.230 0.10860.059 0.02960.015 0.22360.093 0.047360.0357 0.33760.176
WT 16 0.22560.045 1.09060.540 0.13260.071 0.05060.024 0.42860.305 0.056260.0369 0.42060.249
P value NS 0.009 NS 0.004 0.01 NS NS
R6/2 12 Frontal Cortex 18 0.28660.259 3.9861.50 0.36660.181 0.05560.020 0.60560.084 0.016960.0143 0.18760.096
WT 15 0.20760.034 5.1561.51 0.74460.236 0.07160.029 1.24360.253 0.014760.0077 0.25960.088
p value NS 0.021 ,0.001 0.068 ,0.001 NS 0.033
NS: non significant.
doi:10.1371/journal.pone.0018336.t001
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latency to reach the target hole was significantly increased in the
R6/2 mice while the number of targets was significantly lower
(Figure 2), indicating altered short- and mid-term retention
memory in HD mice.
Discussion
Using a microwave fixation system, we found a significant
decrease of DA, 3-MT and HVA in the striatum of R6/2 mice at 8
and 12 weeks of age paralleling motor deficit in these mice. Some
of the dopaminergic alterations were also seen in non-striatal
regions such as hippocampus and frontal cortex, underlining the
early aberrant connectivity of dysfunctional frontostriatal circuits
in HD [22]. Likewise, several studies reported decreased CSF
levels of HVA in HD patients prior to the HTT gene identification
[23,24,25]. Importantly, we showed for the first time that the DA
loss was preceded by altered DA metabolism, i.e. decreased 3-MT
and HVA levels, in striatum and frontal cortex of 4-week-old
motorically asymptomatic R6/2 mice. Indeed, the use of a video-
based behavior-recognition technology allowed us to confirm that
mice sacrificed at 4 weeks of age were at the presymptomatic
motor stages of the disease as previously shown [18,26].
Radiolabeled studies from synaptosomes showed normal DA
release and uptake in R6/2 mice [27], but direct measurements of
DA neurotransmission using fast-scan cyclic voltammetry at
carbon-fiber microelectrodes showed that DA release was severely
compromised in brain slices from 12-week-old R6/2 mice [28].
While some studies hypothesized a deficiency of DA exocytosis
due to impaired vesicular packaging [28], others indicated a
decline in the number of DA reserve pool vesicles available for
mobilization [29]. Since the injection of 3-nitropropionate (3NP) –
an inhibitor of the mitochondrial enzyme succinate dehydrogenase
– in WT mice reproduced the same reduction of DA release, the
altered vesicular packaging was thought to be an ATP-dependant
process [28]. Similarly, progressive declines in striatal D2-receptor
binding were correlated with concurrent hypometabolism in
presymptomatic individuals [30]. While our study does not
directly assess dopamine release, the decreased 3-MT/DA and
HVA/DA ratio in the context of decreased DA levels [31] at 8 and
12 weeks are consistent with more direct measurements of reduced
dopamine release at the same time points [5,29].
Moreover, we demonstrated for the first time that serotonin
metabolism is impaired at the earliest stages in the R6/2
transgenic mouse model of HD. We found that both 5-HT and
5-HIAA were significantly decreased in the striatum, hippocampus
and frontal cortex of 8 and 12-week-old R6/2 mice. Unlike
previous studies that used common sacrificial methods [13], our
study revealed a significant decrease of both serotoninergic
metabolites as early as age 4 weeks in the 3 brain regions that
were analyzed in our HD mice. Serotonin turnover rate, as
suggested by the 5-HT to 5-HIAA ratio, was also likely altered in
R6/2 mice compared to WT littermates starting at 4 weeks of age.
Reduced expression of specific serotonin receptors and serotonin
transporter, as recently reported in pre-motor symptomatic R6/1
mice, may explain this abnormal serotoninergic pattern [32]. Of
note, treating 6-week-old R6/2 mice with sertraline – a selective
serotonin reuptake inhibitors (SSRI) antidepressant – led to
improved survival, motor performance and neurogenesis [33].
The same therapeutic benefits were reported when treating N171-
82Q mice – another transgenic mouse model of HD – with the
SSRI sertraline [34].
The use of an advanced automated video tracking system also
allowed us to identify early behavioural abnormalities in R6/2
mice with increased grooming and jumping at 4 weeks of age.
Jumping was previously shown to decrease in R6/2 mice [18] and
was thought to reflect the locomotor decline in HD mice. By
Table 2. Profile of serotonin metabolites in brain of WT and R6/2 mice at 4, 8 and 12 weeks of age.
GENOTYPE Age REGION N 5-HT 5-HIAA 5-HT/5-HIAA
(weeks) (nmol/g) (nmol/g)
R6/2 4 Striatum 17 6.1461.19** 1.2760.36** 0.20660.042**
WT 18 7.3461.14 2.2660.35 0.31160.045
R6/2 4 Hippocampus 17 6.1260.87** 1.2660.31** 0.20660.044**
WT 18 8.3861.32 2.4760.41 0.30060.059
R6/2 4 Frontal Cortex 16 6.5761.24** 0.6560.23** 0.09960.024**
WT 17 8.5160.86 1.1360.17 0.13360.019
R6/2 8 Striatum 15 5.6760.79** 0.4860.11** 0.08560.017**
WT 15 10.1661.73 2.6160.56 0.25960.045
R6/2 8 Hippocampus 15 5.2360.71** 0.4560.12** 0.08560.020**
WT 15 11.8862.10 3.0360.72 0.25760.048
R6/2 8 Frontal Cortex 15 6.7561.19** 0.2260.05** 0.03360.005**
WT 14 12.3261.69 1.3360.23 0.11060.027
R6/2 12 Striatum 18 4.8561.30** 0.3960.12** 0.08260.015**
WT 15 9.1462.47 2.4660.60 0.27560.046
R6/2 12 Hippocampus 18 5.4061.11** 0.4460.16** 0.08260.023**
WT 16 12.0262.27 3.3060.77 0.27860.055
R6/2 12 Frontal Cortex 18 6.8661.19** 0.2760.18** 0.04160.028**
WT 15 11.8662.01 1.4960.24 0.12860.025
**p,0.001 compared to WT mice.
doi:10.1371/journal.pone.0018336.t002
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jumps, from the HomeCage recording. n=20 animals/group.
doi:10.1371/journal.pone.0018336.g001
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age 8 and 12 weeks by significantly decreased hanging, our data
displayed a clear increase of behaviours such as jumping and
grooming. These repetitive behaviours have been interpreted to
indicate stress [20,21]. Thus, this neuropsychological profile may
be a behavioural correlate of the early serotonin alterations that we
found in R6/2 mice as early as 4 weeks of age. This would warrant
further trials with pharmacological agents altering either serotonin
or dopamine pathways in HD preclinical models in order to better
delineate the link with the early stress-like behaviors that we
observed. Of note, our observation of serotonin depletion in 4-
week-old mice goes along with the efficacy of SSRI antidepressant
drugs or even atypical neuroleptics such as olanzapine – i.e. partial
agonists of 5-HT1 receptors – in treating anxiety and depression at
the early stage of HD. Accordingly, their efficacy is superior
compared to benzodiazepines usually proposed for treatment of
anxiety (A. Durr, personal observation). We also found altered
cognition with decreased spatial learning in 6-week-old R6/2
mice. Considering that serotonin and DA neurotransmitters play a
key role in modulating synaptic transmission in the brain [35], the
combined deficit of both serotonin turnover and DA release likely
underlies the learning and memory deficits that we observed. Of
note, none of the serotonin and DA metabolites correlated with
the number of CAG repeats. This may reflect a threshold effect in
which the magnitude of changes between R6/2 and WT mice –
up to 2-fold difference for some neurotransmitters – would surpass
the specific effect of CAG repeats. The lack of correlation may also
be explained by the narrow range of CAG repeats in our HD
mouse colony.
This is the first study reporting the levels of DA and serotonin
metabolites in different brain regions of WT mice after microwave
fixation. The instantaneous inactivation of brain enzymes by the
microwave prevents post-mortem changes in particular for high-
energy phosphates [36] and phosphorylation reactions [17]. Here
we found that dopaminergic and serotoninergic neurotransmitters
were also sensitive to microwave fixation, and in particular
DOPAC, 3-MT and 5-HT [13]. Consequently, we were able to
detect significant changes in both DA and serotonin metabolism at
very early stages of HD pathology in R6/2 mice that were not
displayed using other sacrificial methods. These abnormal
neurotransmitters profiles mirrored the presence of increased
stress-like behaviours in otherwise motorically asymptomatic 4-
week-old HD mice. Altogether, this study underscores that
neurotransmitters alterations occur early in HD pathogenesis
and that neuropsychological symptoms should be investigated and
treated at the presymptomatic stages of the disease.
Figure 2. Barnes maze test in 6-week-old R6/2 and WT mice. Latency to reach the virtually target hole and numbers of pokes in the target
hole were measured on day 5 (A) and day 12 (B). n=20 animals/group.
doi:10.1371/journal.pone.0018336.g002
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